CDMO Pricing Shifts: Value-Based Models Replacing Cost-Plus in Pharma Partnerships

The pharmaceutical industry is seeing a shift in how Contract Development and Manufacturing Organizations (CDMOs) structure their pricing, according to a recent analysis. Complex pricing models are becoming more common, and there is a move away from traditional cost-plus models toward value-based pricing structures. Transparency and outcome-based pricing are increasingly seen as the future of CDMO partnerships. The analysis highlights the evolving landscape of CDMO pricing models. Cost-plus pricing, where costs are tallied and a markup is added, is being replaced by value-based pricing, which aligns pricing with the outcomes and value delivered. The increasing complexity of these pricing models necessitates that pharmaceutical companies carefully navigate their CDMO partnerships to optimize value. The report also notes the importance of transparency in these agreements.

Newsflash | Powered by GeneOnline AI
Date: April 8, 2025

Related posts:

Generic Drug Makers Increase Pharmacovigilance Efforts as Adverse Drug Reactions Account for 5-10% of Hospitalizations Globally. UK Drug Industry Warns Clawback System Threatens Innovation, Undermining Government’s 10-Year Plan AI Models Analyze Biomarkers to Improve Muscle Atrophy Prediction in Cancer Cachexia Patients Inflation Reduction Act’s Drug Negotiation To Reshape Medicare Drug Pricing, Provider Reimbursement & Healthcare Delivery.

Author

Mark Chiang